Klotho Neurosciences Signs Letter of Intent To Acquire Assets From Turn Biotechnologies, Including Turn's Epigenetic Reprogramming of Age Platform And eTurna RNA Delivery System As Well As Co-Development Partnership Worth Up To $300M
Author: Benzinga Newsdesk | September 30, 2025 07:33am